should be: next investor should pay much more than $4.6 million to get 10% of NSP's PrIME therapeutic plasma business. target the 1.8 billion per year Asia market!
NuSep (ASX: NSP) is pleased to advise the market that it has signed agreements with the Singapore based A-Bio Pharma Pte Ltd, a subsidiary of Luye Pharma Group (SGX:LUYE) (Luye) for them to invest S$6m (A$4.6m) for 10% of NuSep’s Singapore plasma fractionation subsidiary, PrIME Biologics Pte Ltd (PrIME). This values PrIME at S$60m (A$46m).
A$46m is current "Investment valuation" before any substantial progress/achievement.
This is the first $4.6m, the next batch could be $5.6m, the third could be $7m, this is the simple logic.
I totaly agree the first $4.6m will be used on the facilities, as this funding will activate our PrIME therapeutic plasma product business immediately.
When these facilities ready, trial production starts, next investor should pay much more than 10% to get 10% of PrIME therapeutic plasma business.
Compared with the deal with ABS, clearly NSP is free carried the 50% of PrIME, and totally controls the development as operator.
MEM Price at posting:
7.0¢ Sentiment: Buy Disclosure: Held
